FDA Advisers Vote in Favor of Updating COVID Vaccines for XFG Variant

What’s happening

An FDA advisory committee voted overwhelmingly in favor of recommending that COVID-19 vaccines for the 2026–27 season target the XFG variant, which had become the dominant strain in the U.S.

Eight of nine panel members voted in favor, while one abstained because of concerns about limited real-time surveillance data.

What’s changing / Business impact

• Vaccine makers may update formulations again
• Continued COVID booster demand
• Ongoing variant monitoring
• New manufacturing cycles for:

  • Pfizer
  • Moderna
  • Novavax

Why this matters

COVID is increasingly behaving like influenza:

• new strains emerge regularly
• vaccines require periodic updating

To note:

• U.S. disease surveillance has weakened due to funding cuts
• committee members expressed concern about insufficient current strain data